Nebenwirkungen · Ituxredi
Ituxredi 100 mg concentrate for solution for infusion Ituxredi 500 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 21
HOS-152145 · Präparat HOS-100701
The safety profile of rituximab in paediatric patients (aged 6 months to less than 18 years old) with previously untreated advanced stage CD20 positive DLBCL/BL/BAL/BLL was generally consistent in type, nature and severity with the known safety profile in adult NHL and CLL patients. Addition of rituximab to chemotherapy did result in an increased risk of some events including infections (including sepsis) compared to chemotherapy only.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-09T10:02:28Z · SHA-256 65f947c73c59460b3d1812ff80010d6719d500cc410ebccf88cf20b48b9c9fe9 · Passage 9cdb3b2f4d5f798dd86ef7b4f0b0fa2ba0dde595757b90a14df3f4e1f44e5194 · Zeichen 24884–25323 im Abschnitt